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Abstract
Astrocytic gliomas are the most common and lethal form of
intracranial tumors. These tumors are characterized by a
signiﬁcant heterogeneity in terms of cytopathological, tran-
scriptional, and (epi)genomic features. This heterogeneity has
made these cancers one of the most challenging types of
cancers to study and treat. To uncover these complexities and
to have better understanding of the disease initiation and
progression, identiﬁcation, and characterization of underlying
cellular and molecular pathways related to (epi)genetics of
astrocytic gliomas is crucial. Here, we discuss and summarize
molecular and (epi)genetic mechanisms that provide clues as
to the pathogenesis of astrocytic gliomas.
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Gliomas are the most common type of tumors among CNS
neoplasms derived from glial cells. They comprise about
40–45% of the total intracranial tumors (Russel and Rubin-
stein 1989). Based on the tumor morphological features and
tissue structure, gliomas are divided into several subgroups,
the most important of which include oligodendroglial tumors,
ependymal tumors, astrocytic tumors, and mixed gliomas
(oligo-astrocytoma) (Kibirige et al. 1989).
Primary glioma tumors can be formed without any
syndromic background or are created because of certain
syndromes as secondary tumors (Vieregge et al. 1987;
Kibirige et al. 1989). Studies have shown that familial
glioma, which has nothing to do with a speciﬁc genetic
syndrome, can occur as well. However, these types of
gliomas are rare and there is very little possibility of seeing
more than two ﬁrst-degree relatives with glioma. Vieregge
and colleagues investigated the familial glioma in their
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studies. By examining 39 cases of familial gliomas, they
found that 60% of them were suffering sisters and brothers
(Vieregge et al. 1987).
The presence of a genetic predisposition can play a
signiﬁcant role in the emergence and development of
gliomas. For example, neuroﬁbromatosis type I (NF1) and
NF2, Li-Fraumeni syndrome, ataxia-telangiectasia, Turcot
syndrome, tuberous sclerosis, Maffucci syndrome, and
Gorlin syndrome can contribute to the occurrence and
development of gliomas. Gliomas can be detected by the
speciﬁc features of the created glioma and the position of its
formation. For example, pylocytic astrocytoma of the optic
nerve is common in neuroﬁbromatosis type I. However, in
neuroﬁbromatosis type II, spinal cord ependymoma is more
likely to occur (Lewis and Ketcham 1973; Kibirige et al.
1989).
The neuroﬁbromine protein resulting from the expression
of the NF1 gene as a potent tumor suppressor plays a role
in the negative regulation of the signal transduction of RAS
and mTOR in astrocytes. NF1 gene mutations are more
common in mesenchymal glioblastoma subtypes (Hamilton
et al. 1995; Zhu et al. 2005). Gliomas are seen in Turcot
syndrome that main characteristic of which is the creation
of primary neuroepithelial tumors of the central nervous
system. However, the somatic mutations of the APC gene
are rare in primary brain tumors so that no somatic
mutations were detected in 91 cases of neuroepithelial
tumors including gliomas (Mori et al. 1994). Glioblastomas
produced in patients with Turcot syndrome, which are
caused by mismatch repair gene mutations, can have high
survival (Iuzzolino et al. 1994). There is no any clinical
trial or case report where knowledge of a particular
mutation or epigenetic modiﬁcation has had therapeutic
value for the patient.
Astrocytoma and glioblastoma
Definition and features of tissue pathology
In terms of deﬁnition, astrocytoma is a general term which is
used for diffused inﬁltrated tumors, including differentiated
neoplastic astrocytes (Hayat 2012). Astrocytomas or astro-
cytic gliomas can be divided into two main groups including:
(i) a group which is more prevalent and consists of diffused
inﬁltrated tumors. Astrocytoma, anaplastic astrocytoma and
glioblastoma are included in this group, and (ii) a group
which is less prevalent and consists of growth-restricted
tumors. Pilocytic astrocytoma, pleomorphic xanthoastrocy-
toma, subependymal giant cell astrocytoma, and Turcot
syndrome are included in this group (Gladson et al. 2010;
Hayat 2012).
Despite the slow growth of astrocytomas, since these
tumors tend to inﬁltrate and diffuse around the brain, even
the types in which the cells are well differentiated (grade II of
histology) tend to recur. Malignant anaplastic astrocytoma
exhibits an anaplastic diffused process. Increased cellularity,
pleomorphism, unusual nucleus, and mitotic activities are
some evidences for this claim (astrocytoma is responsible for
creating grade III of histology).
Glioblastoma, which is known as the most common
primary malignant tumor of the brain, as well as the most
malign and most common type of glioma (about 50% of the
total gliomas), annually affects about 10 000 people. The
average survival rate of these persons is between 12 and
15 months (Weary et al. 1972; Kibirige et al. 1989; Russel
and Rubinstein 1989).
Glioblastomas are anaplastic tumors, which often have
cells with very small differentiation, conic, round or
pleomorphic shapes and sometimes have multi-nucleus
giant cells. The presence of parameters such as prominent
angiogenesis or necrosis is essential for histological
diagnosis of these tumors. Histologically, glioblastomas are
responsible for creating grade IV (Weary et al. 1972).
The incidence of astrocytoma and glioblastoma in adults is
higher compared to children. These tumors in adults have
about 17% of the brain’s primary tumors. However, this is
only 4% in children (Weary et al. 1972). As noted above,
glioblastomas can occur at different ages, but the incidence
rate varies in different ages. The highest incidence of
glioblastomas is between the ages of 45 and 60 years. Using
computed tomography and magnetic resonance imaging,
these tumors have a ring-like structure with a low density
(necrotic) center surrounded by a ring of contrast-enhancing
vital tumor tissue and edema (Burger and Green 1987;
Kleihues et al. 2002).
Macroscopic appearance of typical glioblastomas is like
large necrotic masses with a peripheral area of the ﬂeshy
gray tumor tissue. Intra-tumor bleeding is common in
them. Since glioblastomas can display a range of cell and
tissue differentiation patterns, the differentiation of these
tumors is very difﬁcult or even impossible in histology
aspect. However, genetically, they can be divided into
distinct primary and secondary tumors. Primary glioblas-
tomas are more common in older people (usually older
than 50). Usually, after a short clinical history (less than
3 months), without clinical and tissue evidence of a less
malignant precursor lesion, they appear to be a new
phenomenon. However, the incidence of secondary
glioblastomas in younger patients (usually less than
45 years) is higher. They are associated with the progres-
sion of malignancy from grade II or III of astrocytoma.
The duration of tumor progression can vary between a
period of less than 1–10 years (with a mean interval of 4–
5 years) (Kleihues et al. 2002). Clinical prognosis of
patients with glioblastoma is very poor and the average
survival time after surgery is only 12 months (Burger and
Green 1987).
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Molecular genetics of astrocytic gliomas
Several molecular mechanisms can lead to the development
of gliomas and the formation of more malignant tissue
features as well as the recurrence of the disease. Some of
these mechanisms include gene ampliﬁcation, rearrangement,
and deletions. The outcome of these mechanisms is the
dominant activity of oncogenes, as well as the recessive
inactivation of suppressive genes.
EGFR
One of the most common genes that is over-expressed in
primary glioblastomas is epidermal growth factor receptor
(EGFR) gene. Over-expression of this gene has been
observed in 60% of cases and ampliﬁcation of gene occurs
in 40% of cases (Ekstrand et al. 1992). EGFR abnormalities
are speciﬁcally associated with glioblastoma multiforme
(GBM), and EGFR ampliﬁcation is associated with a
decrease in the average survival rate of patients (Hurt et al.
1992). The gene encoding EGFR is located on chromosome
7. A frequent observation of trisomy 7 in glioblastoma can be
an evidence for the link between EGFR ampliﬁcation and
GBM (Agosti et al. 1992).
EGFR is structurally a transmembrane protein with
tyrosine kinase activity that contains an extracellular domain
attached to EGF and transforming growth factor alpha
(Fig. 1). The autocrine interaction of this receptor with its
ligand can lead to increased cell proliferation (Agosti et al.
1992; Hurt et al. 1992; Sj€ostr€om et al. 2010). Meanwhile,
EGFR VIII is concurrently expressed as a mutated receptor
in 50% of glioblastomas with ampliﬁcation of EGFR
(Ekstrand et al. 1992; Aldape et al. 2004; Mellinghoff et al.
2005). This EGFR variant powerfully and continuously
contributes to the activation of signaling pathway of the
phosphatidylinositol 30 kinase (Fig. 1) (Choe et al. 2003; Li
et al. 2004; Sordella et al. 2004).
In a study on tumors of 58 patients with glioblastoma, von
Deimling et al. showed that EGFR gene ampliﬁcation is only
observed in tumors which lack chromosome 10. This
suggests that the lack of chromosome 10 can be a cause
for the incidence of EGFR abnormality in the tumor
progression process (Louis et al. 1992). In addition to
over-expression and ampliﬁcation of the EGFR gene,
rearrangements and deletions of this gene can also be one
of the causes of the ligand’s abnormal connection (Ekstrand
et al. 1991; Wu et al. 1993).
Most of the rearrangements are the deletions which
involve the 50 end of the gene. This part of the gene encodes
the extracellular domain of protein. The 30 end of the gene
that encodes the intracellular domain is rarely affected (Louis
et al. 1993). The most common rearrangement is an 801 bp
inframe deletion which results in an incorrect splicing of
exons 1–8. As a result of this false splicing, the receptor
molecule is incompletely expressed. The resulting receptor
lacked some sections of the extracellular domain that are
necessary for binding to the ligand. The functional feature of
this type of EGFR is the continuous activity of tyrosine
kinase, which is likely to increase tumorigenesis in human
glioma cells (Collins 1995).
One potential explanation for the failure of EGFR and
platelet derived growth factor receptor alpha inhibitors to
exert remarkable clinical effects is that other receptor
tyrosine kinases may crosstalk to make an integrated
signaling threshold that is not effectively mitigated through
the inactivation of any single receptor tyrosine kinase (Lu
et al. 2009; De Witt Hamer 2010). In a study on pilocytic
astrocytoma (the most common type of astrocytic tumors in
children), there was no change in the EGFR gene and
absence of alleles in chromosomes 10, 17p, and 19q was
reported (von Deimling et al. 1993).
Murine double minute 2
Over-expression and ampliﬁcation of the murine double
minute 2 (MDM2) gene were reported in a number of
primary glioblastomas. The product of this gene can form a
complex with P53 and inhibit its function (Fig. 1) (Finlay
1993; Biernat et al. 1997; Wang et al. 2011). In their
studies on 157 primary brain tumors, Reifenberger et al.
found that MDM2 gene is ampliﬁed and over-expressed in
8–10% of the anaplastic astrocytomas and glioblastomas. In
addition to examining this mutation, the TP53 gene was
also studied. No mutation in TP53 gene or LOH in 17p was
detected in these tumors. This suggests that the ampliﬁca-
tion of the MDM2 gene may be an alternative mechanism
for abnormally regulated growth control by P53 protein
(Reifenberger et al. 1993; Schiebe et al. 2000; Wang et al.
2011).
Reifenberger et al. also showed that 15% of glioblastomas
and astrocytomas have chromosomal ampliﬁcation of 12q13-
14. Another major ﬁnding of their research was that some
tumors that did not have MDM2 gene ampliﬁcation in their
genome, had genetic ampliﬁcation for the CDK4 and SAS
genes (Reifenberger et al. 1994). It was reported that MDM4
gene is genetically ampliﬁed in gliomas which lack both
TP53 mutation and MDM2 gene ampliﬁcation (Riemen-
schneider et al. 1999).
P53
P53 tumor suppressing gene (Fig. 1) mutations and over-
expression of platelet-derived growth factor ligands in
secondary glioblastomas have been observed (Kleihues
et al. 2002). The presence of P53 mutation in mild
astrocytomas causes tumor tendency for progressive and
aggressive growth (Ohgaki et al. 1993; England et al.
2013). The survival rate estimated by Kaplan–Meier
method for patients with P53 mutation was 21% 5 years
after diagnosis, whereas it was 46% for patients with
tumors lacking P53 immunoreactivity. (Ohgaki et al.
1993).
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MGMT (methyl-guanine methyl transferase) and methylation
Methyl-guanine methyl transferase (MGMT) gene, located on
the chromosome 10q26, is involved in the removal of alkyl
groups from the O6 position of guanine by the production of
a protein involved in DNA repair. Thus, the high activity of
MGMT reduces the therapeutic effects of alkylating agents.
The lack of expression of MGMT can be caused by
epigenetic silencing of MGMT gene promoter via methyla-
tion (Taylor and Schiff 2015). In a study on 206 glioblas-
tomas, the promoter methylation of this gene occurred in
45% of cases, which led to the promoter’s silencing of the
gene and consequently its lack of expression. This change led
to a signiﬁcant increase in the overall survival rate from
12.2 months (in patients without promoter methylation) to
18.2 months (in patients with promoter methylation). In
addition to the beneﬁt of increasing the survival rate, patients
with MGMT methylated promoters beneﬁt from a combina-
tion of chemotherapy (by an alkylating agent such as
temozolomide) and radiotherapy (with an survival of
21.7 months) compared with radiotherapy alone (with an
average survival of 15.3 months) (Hegi et al. 2005; De
Salvo et al. 2011; Juratli et al. 2012; Johnson et al. 2014).
MicroRNAs
Among several factors which are involved in the initiation
and progression stages of astrocytic gliomas, microRNAs
(miRNAs) have emerged as epigenetic regulators and play
key roles in the pathogenesis of many diseases such as
Fig. 1 Different signaling pathways involved
in glioblastom. This ﬁgure represents
different signaling pathways including
EGFR, PDGFR, METR, WNT, and SHH
signaling as well as their downstream
molecules and their connection with each
other. Disturbing the balance of these
pathways can cause gliomas.
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astrocytic gliomas (Sato et al. 2011; Nikaki et al. 2012)
(Gholamin et al. 2016, 2018; Mirzaei et al. 2016a,c,e,
2018a,b; Mirzaei 2017; Rashidi et al. 2017a,b; Hoseini
et al. 2018; Jamali et al. 2018; Moridikia et al. 2018;
Rabieian et al. 2018). miRNAs are short non-coding RNAs
which are involved in many biological processes such as
growth, development, angiogenesis, and differentiation
(Fathullahzadeh et al. 2016; Mirzaei et al. 2016b, 2017b;
Mohammadi et al. 2016; Saadatpour et al. 2016; Salarinia
et al. 2016; Keshavarzi et al. 2017a,b; Golabchi et al. 2018;
Keshavarz et al. 2018; Mashreghi et al. 2018). Increasing
evidence has indicated that miRNAs are associated with the
initiation and progression of several diseases such as
cardiovascular disease, stroke, diabetes, and cancer (Mirzaei
et al. 2016d, 2017a; Banikazemi et al. 2018; Golabchi et al.
2018; Jafari et al. 2018; Masoudi et al. 2018; Saeedi
Borujeni et al. 2018; Simonian et al. 2018; Tavakolizadeh
et al. 2018). Previously, we showed that a variety of
miRNAs are involved in glioblastoma pathogenesis
(Masoudi et al. 2018). It has been revealed that deregulation
of miRNAs in various cells associated (i.e., astrocytes, and
microglia) with gliomas could contribute to the progression
of astrocytic gliomas (Malzkorn et al. 2010; Yang et al.
2014). In a study, Conti et al. (2009) assessed the expression
levels of various miRNAs (i.e., miR-21,miR-221, miR-128a,
miR-128b, miR-128c, miR-181a, miR-181b, and miR-181c)
in human astrocytic tumors. Their results indicated that miR-
21 and miR-221 are up-regulated in glioma samples, while
miR-181b is down-regulated when compared with normal
brain tissue. Moreover, miR-21 was up-regulated in all tumor
samples, whereas higher levels of miR-221 were observed in
high-grade gliomas. These results suggested that the dereg-
ulation of various miRNAs could be associated with different
stages of astrocytic gliomas (Conti et al. 2009).
Recently, Mao et al. (2017) reported a molecular classi-
ﬁcation of astrocytic tumors. Their results indicated that there
are 11 795 DNA methylation sites, 3627 genes, 3334
lncRNAs, and 136 miRNAs that are involved in astrocytic
tumors. Moreover, they observed that some genes (i.e.,
ANK3, TSPYL5, RAB3A, and ABCA2) are hyper-
methylated which lead to their decreased expression in
astrocytic tumors (Mao et al. 2017).
Other genetics alteration
Astrocytic tumors, like other tumors, show genetic hetero-
genity. Different genetic factors from chromosomal changes
to molecular changes have been identiﬁed in astrocytic
tumors. These factors are grouped by chromosome in
Table 1, Fig. 2.
Mutation in isocitrate dehydrogenase (IDH) is one of
major molecular alterations which involved in the pathogen-
esis of grade glioma. IDH1 or IDH2 mutation is observed
that have occurred in more 90% of astrocytomas and
oligodendrogliomas. Besides IDH, ATRX gene mutation is
other important mutations which could be detected employ-
ing immunohistochemistry as loss of nuclear ATRX expres-
sion (Chatterjee et al. 2018). In a study, Chatterjee et al.
(2018), assessed the frequency of IDH1, ATRX, and BRAF
V600E mutations in 80 patients (including 25 diffuse
astrocytoma, 25 glioblastoma, 15 pilocytic astrocytoma,
and 15 anaplastic astrocytoma) with grade astrocytomas
and their prognostic value. Their results indicated that all
patients with pilocytic astrocytoma and primary glioblastoma
were negative for IDH1 mutation. Moreover, low expression
of nuclear ATRX was observed in 87% (20/23) and 100%
(14/14) DA and AA patients, respectively. BRAF V600E
mutation was not diagnosed in any astrocytic tumor. Their
ﬁndings proposed that IDH1 and ATRX mutations are
commonly associated with diffuse astrocytoma and anaplas-
tic astrocytoma, while they are rarely observed in patients
with pilocytic astrocytoma and glioblastoma (Chatterjee
et al. 2018).
In a study, Chen et al. (2016), indicated that mutations or
epigenetic modiﬁcations of IDH1 can provide a survival
advantage to glioma patients. Their results demonstrated that
these mutations improve overall patient survival though
decreasing the ability of cells to produce nicotinamide
adenine dinucleotide phosphate, and consequently lowers the
capacity of the cell to scavenge oxygen species. These events
could make the tumor cells more susceptible to irradiation
and chemotherapy (Chen et al. 2016).
CDKN2/p16 is main deletion which is observed in various
gliomas tumors. P16 is an important regulator which is able
to control a cell cycle cascade and includes cyclin-dependent
kinase 4 (cdk4), cyclin D1, and pRb. It has been observed
that deregulation of each of these proteins are associated with
primary human GBM or in GBM cell lines (Purkait et al.
2015). In a study, Miettinen et al. (1999), assessed the
association of CDKN2/p16 expression and cell proliferation
activity and survival rate of patient with oligodendrogliomas
and astrocytomas. They showed that expression of CDKN2/
p16 was reduced in grade II and anaplastic oligoden-
drogliomas (17/42) and low CDKN2/p16 expression was
related to high histologic cancer grade. Moreover, they
indicated that protein levels of CDKN2/p16 were reduced in
glioblastomas (9/10), anaplastic astrocytomas (5/9), grade II
astrocytomas (3/10) and in none of pilocytic astocytomas (0/
7). Their results revealed that low expression of CDKN2/p16
was also related to high cell proliferation activity and poor
survival rate in patient with astrocytomas. Their ﬁndings
proposed that loss of CDKN2/p16 expression could have
main roles in the progression of oligodendrogliomas and
CDKN2/p16 immunocytochemistry could be employed as a
biomarker in oligodendrogliomas and low-grade astrocy-
tomas (Miettinen et al. 1999).
The Deleted in Malignant Brain Tumors 1 (DMBT1) is
other gene which involved in astrocytic gliomas pathogensis.
DMBT1 is a region of chromosome 10q25.3-q26.1 and its
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Table 1 Cytogenetic and molecular genetics of astrocytic gliomas
Chromo
some Gene Product Features References
1 MDM4
Fig. 1
Murine double
minute 4
• p53 regulator
• Ampliﬁed in gliomas lacking TP53
mutations with lacking MDM2
ampliﬁcation
Riemenschneider et al. (1999) and
Furgason et al. (2015)
2q IDH1
Fig. 2
Isocitrate
dehydro
genase 1
• Encodes an enzyme in the citric acid cycle
• Somatic mutations have been seen in 12%
of glioblastoma multiforme (GBM) tumors
• Mutations:
o Uncommon (5%) in primary adult
GBMs
o Present in 85% of secondary
glioblastomas
o Have been reported in Pediatric gliomas
(rarely)
o The earliest detectable genetic change in
precursor of low-grade diffuse
astrocytomas
o Early event of transformation in tumors
that gain either p53 mutations or
deletions of 1p and 19q
Balss et al. (2008), Capper et al. (2009),
Hartmann et al. (2009, 2010) and
Ohgaki and Kleihues (2013)
4q PDGFRa
Fig. 1
Platelet-derived
growth factor
receptor alpha
• Initiates signal of mitogensis
• Ampliﬁcation in up to 17% of GBMs
• Detected in all four subtypes
• Changes are more common in the proneural
subtype
Fomchenko et al. (2011) and Lokker
et al. (2002)
7 EGFR(7p)
Fig. 1
Epidermal growth
factor receptor
• Chromosome 7 ampliﬁcation is the most
common change in glioblastomas (increase
copy number of EGFR)
• Detected in 50–60% of GBM tumors
• EGFRvIII: a aberrantly active version of
EGFR with evades degradation and
contributes to instability of genome
• Alterations in EGFR are observed in all four
tumor subtypes
• EGFR change is a hallmark of the classic
subtype
Burger and Fuller (1991), Howe et al.
(1989), Verhaak et al. (2010), Li et al.
(2014) and Furgason et al. (2015)
CDK6(7q)
Fig. 1
Cyclin-
dependent
kinase 6
• Commonly up-regulated in gliomas
• Ampliﬁcation and over-expression or
activation of Cdk6 related with human
glioblastoma
Zhu et al. (2013) and Raub et al. (2015)
MET (7q)
Fig. 1
MET proto-
oncogene
(receptor tyrosine
kinase)
• The expression of MET associates with
tumor grade
• Ampliﬁcations of MET in glioma tumors
are far less common than those of EGFR
• In vivo inhibition of MET by antibodies
resulted in reduction of tumor growth
Kong et al. (20090, Wu et al. (2011),
Eckerich et al. (2007) and Martens
et al. (2006)
(continued)
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Table 1. (continued)
Chromo
some Gene Product Features References
• Higher expression is related with a shorter
time to recurrence of tumor
• MET signaling contributes to drug
resistance
• May be critical to cancer stem cells
9p CDKN2A
(MTS1)
Fig. 1
p16 (p16INK4a) • Mutations of CDKN2A have been
recognized in astrocytoma, glioblastoma
and melanoma
• Deletions of one or two CDKN2A gene
copies frequently take place in
Glioblastomas
• CDKN2A homozygous deletion in 41% and
hemizygous CDKN2A loss in 28% of
primary glioblastomas have been observed
• In glioblastoma cell lines, the incidence of
homozygous CDKN2A is even higher (up
to 70%)
• CDKN2A inactivation by point mutation or
through methylation of 50 CpG island has
been found in some glioblastomas
• Deletions of chromosome 9p may occur in
oligodendrogliomas and lower grade
astrocytomas as well as malignant
astrocytomas
• The tumor cells with lack CDKN2A
mutations characteristically have
RB1mutations
• Analysis of molecular subtype of tumors
reveals CDKN2A gene deletion is common
(70%)
• CDKN2A gene deletion take place in 95%
of tumors with the classic subtype
Liggett and Sidransky (1998), Greene
(1999), Schmidt et al. (1994), Ranjit
et al. (2015), Urbschat et al. (2017),
Sippl et al. (2018), Cerchietti and
Melnick (2017) and He et al. (1994)
10 Monosomy
10
• Frequently detected in glioma tumors
• Monosomy 10 is characteristically related
with a more malignant histologic type
• The incidence range of chromosome 10 loss
in glioblastoma tumors in different studies
is from 60% to more than 90% of the cases
• Primary glioblastomas are characterized by
loss of heterozygosity on entire
chromosome 10, while secondary
glioblastomas often illustrate LOH on
chromosome 10q.
• Loss of heterozygosity (LOH) on
chromosome 10 is occurred in up to 80% of
cases
Karlbom et al. (1993), Schrock et al.
(1994), Yadav et al. (2009), Nakamura
et al. (2000), Albarosa et al. (1996)
and Fujisawa et al. (2000)
(continued)
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Table 1. (continued)
Chromo
some Gene Product Features References
• LOH on chromosome 10 is less common
(approximately 40%) in anaplastic
astrocytomas
DMBT1 Deleted in
malignant
brain tumors 1
• Located at distal 10q
• Intragenic homozygous deletions in
DMBT1 were found in about 23% of
glioblastomas
Mollenhauer et al. (1997) and Sasaki
et al. (2002)
MXI1 • Candidate gene that located at distal 10q
• Negatively regulate MYC oncoprotein
function
• MXI1 is a gene with potential tumor
suppressor activity
• Mutations of MXI1 have been discovered in
prostate cancer
Eagle et al. (1995) and Wechsler et al.
(1997)
PTEN
Fig. 1
• PTEN somatic mutations have been
discovered in about 1/3 of glioblastoma
tumors
• Chromosome 10 deletions in region that
containing the PTEN gene, frequently occur
in tumors with EGFR ampliﬁcations
• Mutations of PTEN are detected in 60% of
glioblastoma multiforme (GBM)
• Deletions in the gene region are:
o Far more common (occur in 85% of
tumors)
o Less common in the proneural subtype
• Loss-of-function mutations of PTEN are
typically related with increased drug
resistance and invasive actions
Benitez et al. (2017), Furnari et al.
(2007), Mellinghoff et al. (2005),
Nagata et al. (2004), Bianco et al.
(2003) and Bostrom et al. (1998)
ANXA7 Tumor
supressor
gene
annexin 7
• Located at 10q22–23 region
• Ca2+ and phospholipid-binding protein
• Lack of expression of Anxa7 is associated
with GBM tumors in late-stage
• The relatively higher Anxa7 levels
potentially lead to longer survival for
patients with GBM
• Deletions in ANXA7 occur in 77% of
tumors
• Mutations are detected in 6%
Guo et al. (2013), Yadav et al. (2009),
Bello et al. (1994)
11p • Loss of heterozygosity of markers in 11p
have been shown in malignant astrocytomas
(except HRAS gene)
• Loss is identiﬁed in low-grade and high-
grade glioma tumors
• Probably these events plays a role in early
tumorigenesis
Fults et al. (1992)
(continued)
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Table 1. (continued)
Chromo
some Gene Product Features References
12 CDK4
Fig. 1
Cyclin-
dependent
kinase 4
• CDK4 ampliﬁcation and over-expression
are observed in glioblastoma tumors
• Ampliﬁcation has been detected in 15% of
malignant gliomas
• Tumors with wild type CDK4 are more
probably to comprise RB1 mutations
• Usage inhibitor of CDK4 kinase has
potential for treating primary tumors of
central nervous system such as glioblastoma
Furgason et al. (2015), Raub et al.
(2015), Choi et al. (1970) and
Reifenberger et al. (1996)
MDM2
Fig. 1
Murine
double
minute 2
• A negative regulator of tumor suppressor
p53
• Ampliﬁcation and over-expression of
MDM2 gene have seen in 8–10% of
glioblastomas and anaplastic astrocytomas
• Associate with worse survival
Bello et al. (1995), Toledo and Wahl
(2007) and Reifenberger et al. (1993b)
GLI
Fig. 1
• Transcription factor
• Kr€uppel-like zinc ﬁnger protein
• Activated by ampliﬁcation
• Gli1 modulates the expression of stemness
genes and the self-renewal of CD133(+)
glioma stem cells (GSCs)
Santoni et al. (2013), Yao et al. (2014)
and Kinzler et al. (1987)
13 RB1
Fig. 1
Retinoblas
toma
protein
• The RB signaling network is often disrupted
in GBMs
• Mutations in RB1 were observed in
glioblastomas, particularly when tumors are
wild type of cyclin dependent kinases
• Chromosomal deletions in the region as the
location RB gene are a common event in
GBM (44%), but are less frequent in the
classic subtype
• Hypermethylation of promoter have been
observed signiﬁcantly more common in
secondary glioblastomas than in primary
glioblastomas
Cairncross et al. (1998), Badiali et al.
(1993), Nakamura et al. (2001) and
Gonzalez-Gomez et al. (2003)
14q NFKBIA
Fig. 1
NFKB
inhibitor
alpha
• Constitutive activation of NF-jB is
frequently observed in GBMs
• Monoallelic deletions in the chromosome
14q are detected in nearly 1/4 of GBM
tumors
• NFKBIA have a role in glioblastoma tumor
suppression.
• Because of the existence
of NFKBIA deletions in some cancer stem
cells of glioblastoma, these deletions may
have occurred early in the glioblastoma
pathogenesis.
Consortium, E. C. T. S (1993), Josefa
Bello et al. (1994) and Bredel et al.
(2011)
(continued)
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Table 1. (continued)
Chromo
some Gene Product Features References
• Loss of NFKBIA can be related with
progression of disease and recurrence of
tumor
17 TP53(17p)
Fig. 1
• Chromosome 17p loss is an early and
common event in astrocytomas
• Losses are frequently accompanied by TP53
gene mutation
• Mutations of TP53:
o Are the earliest detectable genetic
change and most common to formation
of secondary glioblastoma
o Present in 60% of precursor low-grade
astrocytomas.
o Are well recognized in glioblastoma
multiform (GBMs) tumors (speciﬁcally
tumors lacking ampliﬁcation of EGFR
and from a proneural subtype)
• Glial tumors incidence in the patients with
Li–Fraumeni syndrome proposed the
important role of the TP53 gene in the
formation of sporadic gliomas
• TP53 inactivation may not be an mandatory
step in tumor development
• Aberrant expression or increased of p53 has
been detected in many astrocytic tumors
(29% of grade 2 tumors and 49% of grade 3
–4 astrocytomas)
Kyritsis et al. (1994), Sameshima et al.
(1992), van Meyel et al. (1994),
Karamitopoulou et al. (1993), Ohgaki
and Kleihues (2007) and Chung et al.
(1991)
NF1(17q)
Fig. 1
Neuro
ﬁbromin 1
• Neuroﬁbromin 1 (NF1) Loss leads to RAS
hyperactivation
• Mutations are found in 17% of GBMs
• 15% to 20% of affected persons with
Neuroﬁbromatosis 1 develop astrocytomas
Obremski et al. (1998), See et al.
(2012) and Lau et al. (2000)
19 • Loss of heterozygosity on chromosome 19p
is a frequent change in astrocytomas
• Alterations on chromosome 19q (involving
19q13.2–q13.4) are less frequently related
to the astrocytomas development
Ritland et al. (1995), Nakamura et al.
(2000) and von Deimling et al. (1994)
22 • Chromosome 22 gain and loss have been
found in malignant gliomas
• In chromosome 22q12 region a novel
ampliﬁcation site was mapped
• Two separate loci affected by regional gains
have been identiﬁed by array-CGH analysis
that contained two candidate genes: TOP3B
and TAFA5
Neumann et al. (1992), Bigner et al.
(1990) and de Stahl et al. (2005)
DMBT1, deleted in malignant brain tumors 1; EGFR, epidermal growth factor receptor; GBM, glioblastoma multiforme; IDH, isocitrate
dehydrogenase, MDM2, murine double minute 2; PDGFRa, platelet derived growth factor receptor alpha.
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homologous deletions and lack of expression in various
malignancies such as medulloblastoma, glioblastoma multi-
forme, lung, and gastrointestinal cancers, has introduced it as
a tumor suppressor gene (Wu et al. 1999).
In a study, Mueller et al. (2002) indicated that the rare
mutations in DMBT1 are associated with astrocytic
gliomas. They used mutational analysis of coding region
of DMBT1, using direct DNA sequencing and single-
Fig. 2 Production of R-2HG as a result of activity of IDH1 mutated gene
and the effects of activity R-2HG on various cellular functions. Mecha-
nisms involved in tumorigenesis induced by the mutation of IDH1. Wild
type of IDH1 (wtIDH1) isoform presents in the cytosol and in a normal
conditions, convert cytosolic isocitrate intoa-KG.Convertingofwt IDH1 to
mutant IDH1 (mIDH1) can be resulted in a-KG conversion to R-
enantiomer of 2-hydroxyglutarate (R-2HG). In addition, this mutation
can decrease the afﬁnity of active site of IDH1 enzyme for isocitrate and
increases it for nicotinamide adenine dinucleotide phosphate and a-KG.
R-2-HG as an ‘onco-metabolite’ encourages tumorigenesis process
through three pathways. (1) R-2HG by inhibiting Eg1N (an a-KG
dependent prolyl hydroxylases (PHD) that causes the hydroxylation of
proline residues in HIF1- a and its degradation by von-Hippel Lindau
protein (VHL)) resulted in persistence of HIF1- a and transcription of
factors induces by it.(2) Other changes caused by R-2HG are epigenetic
alterations. These modiﬁcations can be made at two levels: DNA and
Histones. Tet methylcytosin dioxygenase 2 (TET2) is a DNA modifying
enzyme that is a-KG -dependent and its inhibition may cause DNA
hypermethylation (DNA level). Some of the histone demethylases are a-
KG -dependent. R-2HG as a competitive inhibitor causes histones
hypermethylation (Histone level). (3) The process of changing immature
type IV collagen to mature collagen requires a-KG –dependent PHD for
post-translational modiﬁcations. Inhibition of this reaction can cause
accretion of misfolded collagen in the ER and activating an ER stress
response. Moreover, deﬁciency of perivascular type IV collagen may
encourage failure of the physiological BBB in gliomaswith mutated IDH1.
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stranded conformation polymorphism analysis 79 patients
with astrocytic gliomas. Their results revealed that there
were ﬁve somatic mutations which two of them led to an
amino acid exchange. One pilocytic astrocytoma had two
missense mutations and another pilocytic astrocytoma
carried a somatic mutation which not affecting the
presumed protein. Moreover, there were observed 21 of
the 27 single nucleotide polymorphisms in patients with
astrocytic gliomas. These results suggested that mutation in
DMBT1 could be related to appearance of astrocytic
gliomas (Mueller et al. 2002).
Conclusion
Astrocytic gliomas among the most important CNS tumors
and are associated with a signiﬁcant disease burden world-
wide. Astrocytic glioma is a complex disease and a variety of
internal and external risk factors could be related to its
initiation and progression. Among various risk factors,
deregulation of various mechanisms which could lead to
up/down regulation of genes such as p53, MGMT, EGFR,
and MDM2, has a critical role in the progression of astrocytic
gliomas. It seems that identiﬁcation of underlying molecular
mechanisms related to astrocytic gliomas could contribute to
a better understanding of the pathogenesis and identiﬁcation
of more effective therapeutic strategies.
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